Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Carboplatin 7Gemcitabine 5130-nm albumin-bound paclitaxel 3Paclitaxel 2olaparib 1eryaspase 1camrelizumab 1Injections 1Erythrocyte Count 1Epirubicin 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Capecitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Triple Negative Breast Neoplasms × Erythrocyte Count × Clear all
NCT03674242 2022-08-01

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)

ERYtech Pharma

Phase 2/3 Terminated
27 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡